search button

Efficacy of memantine on neuropsychiatric symptoms associated with the severity of behavioral variant frontotemporal dementia: A six‑month, open‑label, self‑controlled clinical trial

  • Authors:
    • Pan Li
    • Wei Quan
    • Yu‑Ying Zhou
    • Yan Wang
    • Hui‑Hong Zhang
    • Shuai Liu

  • View Affiliations

  • Published online on: April 20, 2016     https://doi.org/10.3892/etm.2016.3284
  • Pages: 492-498
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Previous studies have focused on the curative effects of memantine in patients with mild-to-moderate frontotemporal lobar degeneration (FTLD); however, its benefits in patients with moderate‑to‑severe FTLD have not been investigated. The present study explores the behavioral, cognitive and functional effects of memantine on behavioral variant frontotemporal dementia (bvFTD) in patients with mild and moderate‑to‑severe stage bvFTD. A total of 42 patients with bvFTD completed a 6‑month treatment plan of 20 mg memantine daily in an open‑label, self‑controlled clinical trial. Patients were divided into two groups according to their Mini‑Mental State Examination (MMSE) score: Mild (score, 21‑26); and moderate‑to‑severe (score, 4‑20). Primary endpoints included Neuropsychiatric Inventory Questionnaire (NPI‑Q) and Clinic Dementia Rating (CDR) scores, and secondary endpoints comprised Neuropsychiatric Inventory Caregiver Distress Scale (NPI‑D), MMSE, Montreal Cognitive Assessment (MoCA), Activity of Daily Life (ADL) and Hamilton Depression Rating Scale (HAMD) scores. Memantine treatment had no effect on overall NPI‑Q scores, with the exception of the agitation subdomain in all patients with bvFTD. However, patients with moderate‑to‑severe bvFTD exhibited a better performance than patients with mild bvFTD, demonstrated by improved NPI‑Q total scores and subscales of agitation, depression, apathy and disinhibition. In the moderate‑to‑severe group, CDR and HAMD scores remained stable, but MMSE, MoCA and ADL scores were reduced after 6 months of treatment. Memantine was well‑tolerated in patients. In conclusion, patients with moderate‑to‑severe bvFTD responded significantly better to memantine in comparison to patients with mild bvFTD with regard to their neuropsychiatric scores, while memantine did not present any cognitive or functional benefits in patients with mild bvFTD. A randomized, double‑blind, placebo‑controlled clinical trial with a larger number of patients is required to verify these promising results for patients with moderate‑to‑severe bvFTD.
View Figures
View References

Related Articles

Journal Cover

July-2016
Volume 12 Issue 1

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

  • Journal Metrics
  • Impact Factor: 2.7
  • Ranked Medicine Research and Experimental
    (total number of cites)
International Symposium on Molecular Medicine Conference Banner
The Cancer Story
World Congress on Advances in Oncology and International Symposium on Molecular Medicine Conference Banner
World Academy Of Sciences Banner
Heyday Road Banner

0

Copy and paste a formatted citation
x
Spandidos Publications style
Li P, Quan W, Zhou YY, Wang Y, Zhang HH and Liu S: Efficacy of memantine on neuropsychiatric symptoms associated with the severity of behavioral variant frontotemporal dementia: A six‑month, open‑label, self‑controlled clinical trial. Exp Ther Med 12: 492-498, 2016
APA
Li, P., Quan, W., Zhou, Y., Wang, Y., Zhang, H., & Liu, S. (2016). Efficacy of memantine on neuropsychiatric symptoms associated with the severity of behavioral variant frontotemporal dementia: A six‑month, open‑label, self‑controlled clinical trial. Experimental and Therapeutic Medicine, 12, 492-498. https://doi.org/10.3892/etm.2016.3284
MLA
Li, P., Quan, W., Zhou, Y., Wang, Y., Zhang, H., Liu, S."Efficacy of memantine on neuropsychiatric symptoms associated with the severity of behavioral variant frontotemporal dementia: A six‑month, open‑label, self‑controlled clinical trial". Experimental and Therapeutic Medicine 12.1 (2016): 492-498.
Chicago
Li, P., Quan, W., Zhou, Y., Wang, Y., Zhang, H., Liu, S."Efficacy of memantine on neuropsychiatric symptoms associated with the severity of behavioral variant frontotemporal dementia: A six‑month, open‑label, self‑controlled clinical trial". Experimental and Therapeutic Medicine 12, no. 1 (2016): 492-498. https://doi.org/10.3892/etm.2016.3284